Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I-II Study of bi-Weekly Fixed Dose Rate Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma

NCT00350961 is registered in ClinicalTrials.gov with Rigshospitalet, Denmark as lead sponsor.

NCT NCT00350961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00350961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I-II Study of bi-Weekly Fixed Dose Rate Gemcitabine, Oxaliplatin and Capecitabine in Patients With Advanced Cholangiocarcinoma
Lead sponsor
Rigshospitalet, Denmark
Phase
Phase 1/2
Overall status
Completed
Start date
June 30, 2004
Completion date
February 29, 2008
Enrollment
39 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

cholangiocarcinoma